Targeted drugs, such as FGFR2 inhibitors and IDH1 inhibitors, block tumour cell proliferation and signalling pathways, thus increasing the effectiveness of immunotherapy and restoring the ability of the immune system to recognize tumours (116, 117). Here, IDH1 is linked to neoplasm.